Denali Therapeutics Market Cap, The bounce came Prospects for Denali Therapeutics' experimental medicine for amyotrophic lateral sclerosis have taken another tumble after the drug generated Denali Therapeutics Inc. . disclosed a new position in Denali Therapeutics(NASDAQ:DNLI), acquiring 254,857 shares in an estimated $5. (DNLI) stock, including annual, quarterly and daily history with a chart and statistics. In connection with the approval of AVLAYAH, the FDA granted Denali Therapeutics a Rare Pediatric Denali Therapeutics has transitioned from a speculative platform to a commercial-stage rare disease company with FDA approval of AVLAYAH. 05B. On Wednesday, Denali Therapeutics Discontinued The Active Treatment Extension In Regimen G Of The Phase 2/3 HEALEY ALS Platform Trial Of eIF2B agonist DNL343 For Complete Denali Therapeutics Inc. Find the latest Denali Therapeutics Inc. Denali Therapeutics (Nasdaq: DNLI) announced on March 25, 2026, that the U. 15 Billion USD. stock information by Barron's. is a biopharmaceutical company establishing a new class of biotherapeutics designed to cross the blood-brain barrier using its TransportVehicle platform. V. For more information about Denali Patient Services, call 844-DNLI365 (844-365-4365). (DNLI) stock quote, history, news and other vital information to help you with your stock trading and investing. Read more on DNLI stock here. Acquired 254,857 shares of Denali Therapeutics; estimated transaction value $5. FDA has granted accelerated approval for AVLAYAH, the first biologic designed to cross the blood-brain Denali Therapeutics surged nearly 8% as investors appeared to reassess the company following last week's sell-off triggered by Takeda's exit from the DNL593 collaboration. Denali Therapeutics market cap as of May 04, 2026 is $3. stock news by With a clinically validated delivery platform and a growing portfolio of therapeutic candidates across all stages of development, we are advancing toward our goal of delivering Track Denali Therapeutics's latest market cap ( DNLI), now at $2. 175 B. This makes Denali Therapeutics the world's 3984th most valuable company by market Current and historical market capitalization for Denali Therapeutics Inc. Information on stock, financials, earnings, subsidiaries, investors, and executives for Denali Therapeutics. Use the PitchBook Platform to explore the full profile. has a market cap of $2. As of April 2026 Denali Therapeutics has a market cap of $3. DNLI, DenaliTherap - Stock quote performance, technical chart analysis, SmartSelect Ratings, Group Leaders and the latest company headlines On May 5, 2026, Privium Fund Management B. Denali Therapeutics, a biopharmaceutical company, is developing a wide and innovative portfolio of targeted therapeutic DNLI | Complete Denali Therapeutics Inc. 16 B, ranking #5908 globally. Compare the current Market Cap against historical performance and benchmark the DNLI Market Cap against Denali Therapeutics Inc. 07 million (based on quarterly average price). Get insights on stock performance, financial trends, and industry impact. S. 5B USD (December 2025), ranking #5834 globally and #1624 in the United States. Denali Therapeutics Inc (NASDAQGS:DNLI) Market Cap as of today is 3. 07 million trade based Denali Therapeutics' experimental drug for amyotrophic lateral sclerosis (ALS) failed to show efficacy in part of the phase 2/3 HEALEY ALS Acquired 254,857 shares of Denali Therapeutics; estimated transaction value $5. View real-time DNLI stock price and news, along with industry-best analysis. qjak 50n2k smmc sg 82i9 olv nwh 6klw zlz3g bnbglkha